Dear friends and partners,
Thank you for your full support and firm recognition! Linkchem will participate in the CIS-Asia 2023 12th Annual ChemPharma International Summit - Asia. We sincerely invite you to visit our booth to discuss about CMC innovative drug development and industry development.
Date: March 16 - 17, 2023
Location: International Convention Centre Hotel Society Hill Tianjin
Organizers: Best Media, Chinese Pharmaceutical Association Pharmaceutical Engineering Professional Committee
Booth No.: T85
Meanwhile, you are also very welcome to attend our keynote speech at 9:30 a.m. on March 17, and panel discussion at 5:15 p.m. on March 16.
Forum 2: Development of APIs for New Drugs
Topic: How to Select and Further Optimize API Processes during the Development of New Drugs?
Date & Time: March 16 at 5:15 p.m.(Forum 2)
Topic: The Art of Small Molecule Drug Synthetic Route Design and Process Scale-up
Date & Time: March 17 at 9:30 a.m.(Forum 2)
Vice President and Chief Technology Officer（CTO）
Dr. Zhong joined Linkchem in October 2022, and is the vice president and chief technology officer (CTO) of the company. He graduated from the Department of Chemistry, Sun Yat-sen University with a B.Sc. and a M.Sc. in organic chemistry, and taught for many years, during which he won two collective awards: Guangdong Province University Prize for Progress in Science, and Guangdong Province Second Prize Award in Natural Science. From 1995 to 1998, he obtained a Ph.D. in organic chemistry under the supervision of Professor Shing, Kung Ming Tony, Department of Chemistry, at the Chinese University of Hong Kong. In 1998, he was invited by Professor K. C. Nicolaou and completed Postdoc at UC San Diego, Scripps Research Institute until mid-2001. Dr. Zhong served at Merck's Research and Development Process in Rahway, New Jersey, USA since June 2001. He successively held the positions of Senior Scientist, Research Scientist and Principal Scientist, engaging in the design, research and development, optimization and commercialization of small molecule drug synthesis routes.
In Merck’s 21-year process research and development career, Dr. Zhong was one of the key contributors to the design and development of commercial synthetic routes for 4 marketed drugs, Isentress, Grazoprevir, Relenactam and Vibegron, and led the design, development and production of a large number of API GMP routes for Merck’s drug candidates (all stages ranging from PCC to pre-commercial production). He has published over 90 scientific papers, 3 book chapters and filed 20 invention patents. Dr. Zhong has a strong industry background, outstanding innovation ability and rich experience in drug synthesis process design, development and management.
In this conference, Linkchem will set up a special booth on site. You can communicate with our scientists and business team face to face. If you need to make an appointment, please email: email@example.com. We will contact you as soon as we receive your appointment information!